Keyphrases
Epstein-Barr Virus
100%
Single Institution
100%
Leukemia-lymphoma
100%
Pathological Examination
100%
Aggressive Natural Killer Cell Leukemia
100%
Epstein-Barr Virus-positive
57%
Overexpression
28%
Programmed Death-ligand 1 (PD-L1)
28%
Natural Killer Cells
28%
Bone Marrow
28%
Clinical Course
28%
Polycomb Repressive Complex 2 (PRC2)
28%
Genetic Modification
14%
Immunohistochemistry
14%
Liver
14%
African American
14%
Peripheral Blood
14%
Pathogenic Mechanism
14%
Neoplasms
14%
Putative Drug Targets
14%
Next-generation Sequencing
14%
Gene mutation
14%
JAK-STAT Pathway
14%
Spleen
14%
Lymph Node
14%
Associated Proteins
14%
Associated Genes
14%
Ancillary
14%
Pleomorphic
14%
Highly Aggressive
14%
Infiltration
14%
Early Recognition
14%
Enhancer of Zeste Homolog 2 (EZH2)
14%
H3K27me3
14%
High Prevalence
14%
Neoplastic Cells
14%
Aggressive Disease
14%
Constitutional Symptoms
14%
C-Myc
14%
Cell Phenotype
14%
Immune Checkpoint Molecules
14%
Complex Karyotype
14%
Azurophilic Granules
14%
Atypical Phenotype
14%
Natural Killer T-cell Lymphoma
14%
Postmortem Examination
14%
Lymphocytosis
14%
Hepatosplenomegaly
14%
Medicine and Dentistry
Epstein Barr Virus
100%
Aggressive NK Cell Leukemia
100%
Diseases
30%
Disease Course
20%
Gene Mutation
20%
Polycomb Repressive Complex 2
20%
Programmed Death-Ligand 1
20%
Natural Killer Cell
20%
Prevalence
10%
Neoplasm
10%
Azurophilic Granule
10%
Lymph Node
10%
Constitutional Symptoms
10%
NK T Cell Lymphoma
10%
Fulminant
10%
Transcription Factor EZH2
10%
Lymphocytosis
10%
Hepatosplenomegaly
10%
CD3 Antigen
10%
Immunohistochemistry
10%
JAK-STAT Signaling
10%
Karyotype
10%